Last year, the US FDA approved a record 59 new drugs, which included 19 first-in-class agents, 34 novel drugs for rare diseases, and a record seven biosimilars.In 2017, 46 new drugs had been approved; in 2016, 22 drugs received the FDA green signal and in between 2009 and 2017, on an average 33 new drugs were accorded FDA approval.
Read the full story.
Create a free account.
To continue reading this article
Sign in with Medtalks
Sign in with Facebook
Continue reading your article with a eMediNexus account.